Peripheral artery disease (PAD) is associated with a linearly increased risk of venous thromboembolism (VTE) after lower extremity revascularisation. A secondary analysis of the VOYAGER PAD study showed that adding low-dose rivaroxaban to aspirin reduced VTE risk by 39% . In another analysis of VOYAGER PAD, rivaroxaban reduced the composite endpoint of major cardiovascular (CV) and limb events in PAD patients with chronic kidney disease (CKD) .
In the VOYAGER PAD study (NCT02504216), patients with lower extremity PAD undergoing revascularisation were randomised to rivaroxaban 2.5 mg twice daily plus aspirin (n=3,286) or placebo plus aspirin (n=3,278) . The primary efficacy outcome of CV death, acute limb ischaemia, major amputation, myocardial infarction, or stroke occurred in 17.3% and 19.9%, respectively (HR 0.85; 95% CI 0.76–0.96; P=0.0...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Sotatercept: potential new treatment option for PAH Next Article
Transient drop in erectile function seen after prostate biopsy »